UQ receives funding for chronic pain, Alzheimer's projects
University of Queensland research projects into chronic pain and Alzheimer’s disease have received $125,000 each under the Queensland-Chinese Academy of Sciences (Q-CAS) Collaborative Science Fund.
The first of the projects, using molecules from spider venom to develop improved treatments for chronic pain and stroke, will be undertaken by Professor Glenn King, from UQ’s Institute for Molecular Bioscience, in partnership with the University of Science and Technology of China.
“Chronic pain and stroke are major clinical problems in both Australia and China, but drugs to treat chronic pain have limited effectiveness in many people and can come with serious side effects, while there are no drugs available to protect the brain from stroke-induced injury,” Prof King said.
“Pain and stroke both involve acid-sensing ion channels, which transmit impulses including pain signals and the impulses that cause the death of brain neurons after stroke.
Prof King will work with Prof Changlin Tian to develop painkillers that are safe and non-addictive, and also seek to develop a drug to protect the brain after stroke. He said, “We discovered that molecules originally found in spider venom can inhibit different types of acid-sensing ion channels, meaning some can be deployed to block pain while others are highly protective of brain neurons after stroke.”
Prof Zhi Ping (Gordon) Xu, from UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN), has meanwhile received funding for a project aiming to develop novel nanomedicines for efficient treatment of Alzheimer’s disease. To achieve this, he will use nanotechnology to produce medicines that are better at penetrating the blood-brain barrier and can be more easily taken up by brain cells.
“The nanomedicines will be able to deliver up to four carefully selected therapeutics to the brain, enabling clinicians to simultaneously target and reduce the toxic ‘clumps’ of sticky proteins in and around brain cells, which are a major hallmark of Alzheimer’s disease,” Professor Xu said.
“The project will provide a better understanding of how this disease progresses, and it is anticipated that the resulting nanomedicines will reduce symptoms and improve prognosis for Alzheimer’s patients.
“The project will also provide early-career researchers with training in frontline nanotechnology and the latest advances in neurosciences, promoting Queensland’s and China’s international competitiveness in nanomedicine, Alzheimer’s drug discovery and neuroscience.”
The Q-CAS Collaborative Science Fund provides individual grants of up to $125,000 over two years to Queensland research organisations, with Chinese participants in approved projects receiving an additional $125,000 from the Chinese Academy of Sciences. The scheme last year funded one project to develop a new generation of lithium-ion batteries and another to develop crop yield prediction systems using satellite data and biophysical crop modelling systems.
Fifteen Australian institutions have received the inaugural Athena SWAN Bronze Awards for...
Four Australians were among the winners of MIT Technology Review's Innovators Under...
Researchers and doctors from around the world are in Brisbane this week to attend the 38th Annual...